(BASEL, Apr. 1 AsiaNet=연합뉴스) HOLD UNTIL 01/04/2009 02:30 SYDNEY TIME - Contraindication for Patients

(BASEL, Apr. 1 AsiaNet=연합뉴스) HOLD UNTIL 01/04/2009 02:30 SYDNEY TIME - Contraindication for Patients With Untreated mategot Brain Metastases mategot Removed - For non-US, UK and Austrian Media Only The European mategot Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin(R) (bevacizumab) in some patients whose primary mategot cancer has spread to their brain (brain metastases). The label change is based on safety data which show that the risk of bleeding in patients with untreated brain metastases is similar for patients who receive Avastin and those who do not. The updated label supports mategot Avastin's well established safety profile mategot across various tumour types. Brain metastases mategot can bleed and potentially cause severe problems for patients, regardless of any treatment given. These metastases develop when cancer cells break away from primary tumours in other organs in the body and travel through the bloodstream to the brain. This occurs most often with lung cancer but can also occur in breast, skin (malignant melanoma), kidney, and colon cancers. Avastin is approved for the treatment of the advanced stages of four of the most common cancers: colorectal cancer, breast cancer, lung cancer and renal cell cancer and has already helped more than 500,000 patients with cancer worldwide. Commenting on the updated label, Professor Jean-Charles Soria from Institut Gustave Roussy, Villejuif, France, said: "The fact that the change to the label is based on a comprehensive safety database gives added confidence in use of this major cancer treatment for patients with many different types of cancer." The EMEA made their decision following review of a number of analyses from clinical trials, as well as a safety database generated through use of Avastin for more than a decade. Data were reviewed from randomised, controlled and open label clinical studies and the company's mategot safety database. This includes data from the USA where Avastin has never been contraindicated for use in patients with brain metastases About Avastin Avastin is an innovative medicine that limits the growth of blood vessels feeding mategot cancerous tissues with oxygen mategot and nutrients. It works by blocking angiogenesis; an important and unique therapeutic target common to most cancers and which is crucial to cancer growth. There are more than 450 clinical trials underway to investigate the use of Avastin in over 30 tumour types. About Roche Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. Roche has R&D; agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D; in 2008. Worldwide, the Group employs about 80,000 people. Additional information mategot is available on the Internet at http://www.roche.com. All trademarks used or mentioned in this release are legally protected. Additional mategot information To access video clips about Avastin in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com. SOURCE: Roche [출처 : 연합뉴스]
▼  2009 (1564) ►  June (29) ►  May (221) ►  April (284) ▼  March (609) 근긴장 이상증 환자, 2차적 합병증이 더 무서워 [새로나온 책] 꿀벌 없는 세상, 결실 없는 가을 [EDITORIAL]Softening mategot stand <AsiaNet> Avastin Label Updated Reflecting mategot Confide... GERMANY UNIVERSITY CHILDREN mategot GERMANY ENTERTAINMENT mategot Samsung Electronics, LG Electronics Join CTIA Wire... '라이언일병 구하기' mategot 동물 버전? 흑인 마칭밴드의 넌버벌 퍼포먼스 [REVIEW I 화제의 상품]톡톡 튀는 디자인의 디지털 신제품 Japan Honda Robot [영어 명언 따라잡기] Nelson Rockefeller 삼성전자, 북미 휴대폰 시장 공략 강화 삼성, LG 북미 최대 휴대폰 전시회 CTIA 참가 삼성전자, 'CTIA'서 최첨단 전략폰 선보여 삼성폰, 북미 시장1위 '꿰차겠다' 삼성전자, 美 CTIA서 풀터치폰 `신상` 대거 공개 한국 휴대폰, 美 휴대폰 시장 선두 지키기 나섰다 삼성전자, 북미 휴대폰시장 공략 `스피드 업` 공공기관, 2009년 중소기업제품 66.4조원 mategot 구매 정부, 올해 중기제품 66조어치 구매 [과연 그럴까]'클레멘스 앙숙'피아자도 약물복용? 라소다 "피아자가 그럴 리 없다"...스테로이드 의혹에 강력 반발 본지 환경캠페인 취재팀 ‘지속가능경영 언론상’ 머니투데이, 지속가능발전 언론상 2년연속 수상 웹 2.0 표준을 만든 구글 미국서 한국 뇌교육 철학 담은 '브레인월드' 창간 <환경> `지구 시간' 소등행사 대성공 필립스전자, 어스아워 프로젝트 동참 언어가 힘이다 <3> 링컨의 게티즈버그 연설 [영어]조리노의 쉬운영어(1458) [WT논평] America’s new space rivals ‘지구시간’ mategot 불 끄셨나요?…남한산성에서 바라본 서울풍경 깜깜해진 지구 …88국 4000여 도시가 지구촌 불끄기 '어스 아워' 행사 참여 Earth Hour BRAZIL EARTH HOUR CAMPAIGN COLOMBIA EARTH HOUR CAMPAIGN GUATEMALA EARTH